The pattern has become an ecosystem cliché: a biomedical engineer at UBC spins out a device company, spends two years validating technology through a clinical partnership at Vancouver General or BC Children’s, secures a seed round from a local angel syndicate—and then relocates to San Diego or Minneapolis to raise a Series A and navigate the FDA. The talent originates here. The intellectual property leaves with them.

The data behind that pattern is stark. Series A medtech rounds in Canada averaged US$8 million in 2024, compared to US$22 million in the United States, according to PitchBook. This structural gap forces founders to choose between undercapitalizing their regulatory pathway or moving to a market where the capital exists. Most choose to move.

BC’s life sciences sector is substantial. Life Sciences BC reported more than 35,000 employees in the sector provincially as of 2024, a figure that has grown steadily over the past decade. The province has invested heavily in research infrastructure, including the Michael Smith Genome Sciences Centre and the BC Cancer Research Institute. UBC’s University-Industry Liaison Office has disclosed approximately 50 active licensing agreements in the life sciences in its most recent annual report—a credible pipeline of early-stage commercial activity.

The problem is not the pipeline; it is what happens at the end of it.

Medical device commercialization in North America runs through the FDA. The U.S. regulator’s 510(k) and De Novo clearance pathways are the gatekeepers for any device company targeting the world’s largest healthcare market. While Health Canada maintains its own licensing process, the commercial logic is clear: build for the FDA first, and the Canadian market follows. That reality creates a gravitational pull toward U.S.-based operations and investor networks.

This pull is amplified by the absence of dedicated Canadian infrastructure. The United States has MedTech Innovator, a national accelerator with direct connections to health systems, strategic investors, and FDA advisors. Canada has no federal equivalent. MaRS Discovery District in Toronto runs a life sciences practice, but MaRS' own sector reporting confirms that while the pipeline is healthy, the commercialization infrastructure remains thin.

For BC, the gap is compounded by geography. Minnesota’s medtech cluster is a direct flight away and culturally familiar to Canadian founders. California offers venture depth and FDA consultants on every corner. Vancouver, for all its research strengths, currently lacks the capital density and regulatory support infrastructure that a device company requires between prototype and first commercial sale.

The retention case is not abstract. Every medtech company that relocates south takes high-wage engineering and regulatory jobs with it, removes an anchor tenant from the local cluster, and reduces the probability that its founders will mentor the next generation of Vancouver device companies. Over a decade, this loss is the difference between a mature cluster and a perpetual feeder system for other ecosystems.

Keeping companies here requires three interventions. The first is capital: a dedicated medtech fund at the Series A tier, either through BDC Capital scaling its life sciences mandate or through a provincial co-investment vehicle structured for device companies. The second is regulatory navigation support—a provincially or federally funded FDA advisory service. The third is a dedicated medtech accelerator with embedded clinical validation pathways, reimbursement expertise, and warm introductions to U.S. strategic investors.

These are not novel ideas; Toronto has iterated on versions of all three. What BC has not done is build them in combination, at scale, with the explicit mandate of competing for company retention rather than simply celebrating research output.

Genome BC’s portfolio and UBC’s commercialization pipeline represent a rolling inventory of companies that will face this decision in the next 24 to 36 months. The question for policymakers and the local venture community is whether they want to be the infrastructure those companies find when they look for a reason to stay—or the origin story those companies mention in a San Diego office announcement.

The talent, research, and early validation infrastructure are here. What is missing is the conviction and the capital to build the next layer. It is a solvable problem; it just requires the decision to solve it.